Obesity Raises Odds for Recurrence in Breast Cancer Survivors

Indonesia Berita Berita

Obesity Raises Odds for Recurrence in Breast Cancer Survivors
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 dothaneagle
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 59%

WEDNESDAY, Oct. 18, 2023 (HealthDay News) -- Many breast cancer survivors take a hormonal drug after cancer treatment to stave off a recurrence, but new research suggests these drugs may

Breast cancer cells in hormone-positive breast cancers are fueled by the female sex hormone estrogen. Aromatase inhibitor medications lower estrogen levels by stopping an enzyme in fat tissue called aromatase from changing other hormones into estrogen.

People are also reading… However, he added, “Treatment with aromatase inhibitors is still the treatment choice for this patient group and lowers the rate of breast cancer recurrence and in this patient group.” “The underlying mechanisms are multifactorial, and further clinical studies to understand how obesity is linked to breast cancer progression are needed,” Harborg said.

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | Omny StudioWhile more studies are needed to see how weight affects the risk of breast cancer recurrence in women taking aromatase inhibitors, it is known that being overweight or obese increases the risk of complications after surgery to treat breast cancer, said Dr.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

dothaneagle /  🏆 337. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Eli Lilly's Obesity Drug Helped People Lose 25% of Their Weight in Latest TrialEli Lilly's Obesity Drug Helped People Lose 25% of Their Weight in Latest TrialPeople who already lost weight at first went on to shed substantially more pounds than those on a placebo, Eli Lilly's newest clinical trial found.
Baca lebih lajut »

New 'Twincretin' Pemvidutide: Another Option for ObesityNew 'Twincretin' Pemvidutide: Another Option for ObesityUnlike tirzepatide, which combines weight loss and glucose-lowering properties, this 'twincretin' reduces liver fat along with weight, blood pressure, and lipid levels.
Baca lebih lajut »

Is Childhood Obesity a National Public Health Emergency?Is Childhood Obesity a National Public Health Emergency?While medical experts have viewed childhood obesity as an epidemic and a crisis for years, some are now saying it’s time to focus even more attention on the situation, and to do so earlier rather than later.
Baca lebih lajut »

Unlocking the Secrets of Fat Tissue: The Inflammatory Response in ObesityUnlocking the Secrets of Fat Tissue: The Inflammatory Response in ObesityScience, Space and Technology News 2023
Baca lebih lajut »

Johnson & Johnson beats earnings estimates, downplays obesity drugs’ impact on its med-tech businessJohnson & Johnson beats earnings estimates, downplays obesity drugs’ impact on its med-tech businessCompany raises full-year profit and sales guidance and pursues multipronged strategy to address talc-powder litigation
Baca lebih lajut »

Study reveals surprising insights into dog sterilization, obesityStudy reveals surprising insights into dog sterilization, obesityAs researchers continue to delve into the effects—both negative and positive—of spaying and neutering dogs, data included in a recent scientific publication in the Journal of the American Veterinary Medical Association indicate that obesity rates in sterilized dogs vary by breed size.
Baca lebih lajut »



Render Time: 2025-02-28 16:47:54